Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dollar Tree, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Dollar Tree, Inc. trades at $124.75 (market cap $24.00B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DLTR | |
|---|---|---|
Market Cap | $39.89B | $24.00B |
Sector | Health | Health |
52-Week High | $491.22 | $141.21 |
52-Week Low | $278.09 | $85.04 |
Enterprise Value | $38.15B | $30.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Dollar Tree (DLTR) trades at $124.91, up 3.3% today, with a bullish technical signal and strong recent earnings beats. The company shows robust profitability with a 34.71% ROE and announced a $2.5 billion share repurchase authorization in July 2026. Revenue for 2025 was $17.58 billion, though net income was negative due to a significant tax charge, while 2026 projections indicate a return to profitability.
The outlook is positive with analyst consensus favoring Buy ratings and a $131 price target. Key opportunities include margin expansion and multi-price strategy gains, but risks involve consumer traffic softness and cost pressures from tariffs and fuel. The stock's valuation appears reasonable with a P/E of 20.05, supporting a measured bullish stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
